ecancer
Avatar

ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefit vs. Sorafenib as 1L Treatment for Unresectable HCC

By ecancer FEATURING Richard S. Finn
By ecancer FEATURING Richard S. Finn
37 views
September 30, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

21:24
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

Featured Video

18:17
Exelixis

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Related Videos

Houston Methodist

Inaugural Houston Methodist Neal Cancer Center GI Oncology Symposium

Fri, Dec 6, 2024
57:44

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

5.1K views
18:21

GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

452 views
29:25

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views
22:55

ASCO® 2023 Summary: "GI Key Studies Including PROSPECT, HERIZON-BTC-…

Insights from 2023 ASCO® Annual Meeting

R. Kim, R. Mehta

3.1K views
20:09

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunot…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

385 views
10:57

Y90 Radioembolization for Locally Advanced HCC

UCLA Health

S. Padia

638 views
13:05

ESMO 2024 Summary: Highlights in HCC

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

202 views
04:39

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - P…

2024 ESMO Annual Meeting Insights Hub

J. Llovet

201 views
15:30

Updates in Combination Therapy for HCC

Yale Cancer Center

S. Stein

456 views
20:07

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

255 views
25:09

ASCO® 2024 Summary: "Experts Discuss Key Studies in HCC and BTC"

2024 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi

378 views
26:59

2023 AASLD Guidance for HCC

University of Texas Southwestern Medical Center

A. Singal

816 views
09:56

ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvaluma…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

170 views
16:40

Year in Review: Hepatobiliary Cancers

Moffitt Cancer Center

R. Kim, T. Biachi

604 views
27:48

Current Approach to Frontline Systemic Therapy for Advanced Hepatoce…

Lionel Kankeu Fonkoua

262 views
15:53

Understanding HCC: Perspectives on Diagnosis, Risk Factors, and Trea…

Yale Cancer Center

A. Jaffe

331 views
13:58

ASCO® GI 2024 Summary: "HCC Key Studies Including EMERALD-1 & IMbrav…

Insights from 2024 ASCO® GI Annual Meeting

R. Kim, T. Biachi

434 views
05:40

ESMO 2024 Insights: CheckMate 9DW Expanded Analysis - Nivo + Ipi vs.…

2024 ESMO Annual Meeting Insights Hub

H. Karachiwala

133 views
14:28

ESMO 2024 Summary: Updates in HCC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

H. Babiker

156 views
03:26

Expert Panel on TACE and TARE for HCC: Weighing the Pros and Cons

Integrity CE

M. Pishvaian, R. Salem

84 views
AUTOPLAY